Tab%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520linagliptin

# Linagliptin ## Overview Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone concentrations (GLP-1 and GIP), stimulating glucose-dependent insulin release and decreasing glucagon levels. It has a unique non-renal primary route of elimination. ## Primary Indications Type 2 diabetes mellitus (T2DM) as an adjunct to diet and exercise to improve glycemic control. ## Adult Dosing 5 mg orally once daily. May be taken with or without food. ## Pediatric Dosing Safety and efficacy have not been established in patients younger than 18 years. ## Dose Adjustments * **Renal Impairment:** No dose adjustment necessary for any stage of renal impairment (including end-stage renal disease). * **Hepatic Impairment:** No dose adjustment required. * **Strong CYP3A4/P-gp Inducers:** (e.g., rifampin) If co-administration is necessary, consider alternative agents or increased glucose monitoring, as linagliptin efficacy may be reduced. ## Contraindications * History of hypersensitivity reaction to linagliptin (e.g., anaphylaxis, angioedema, exfoliative skin conditions). * Type 1 diabetes or diabetic ketoacidosis. ## Adverse Effects * **Common:** Nasopharyngitis, hypoglycemia (when used with insulin or sulfonylureas). * **Serious:** Acute pancreatitis (discontinue immediately if suspected), bullous pemphigoid, severe arthralgia (joint pain), and hypersensitivity reactions. ## Key Drug Interactions * **Strong CYP3A4/P-gp inducers:** May decrease linagliptin serum concentrations (e.g., rifampin, carbamazepine, phenytoin). * **Secretagogues/Insulin:** Risk of hypoglycemia is increased; consider dose reduction of the secretagogue or insulin when adding linagliptin. ## Monitoring * **HbA1c:** Typically monitored every 3–6 months. * **Blood Glucose:** Periodic self-monitoring. * **Pancreatitis Symptoms:** Monitor for severe, persistent abdominal pain. * **Skin:** Evaluate for blistering or erosions suggestive of bullous pemphigoid. ## Clinical Pearls * Linagliptin is the only DPP-4 inhibitor that does not primarily rely on renal excretion; it is eliminated via the biliary-fecal route, making it favored in patients with chronic kidney disease. * It does not cause weight gain. * The risk of hypoglycemia is low unless combined with sulfonylureas or insulin. * Discontinue therapy if severe or persistent joint pain occurs. *** **Educational Disclaimer:** This information is for educational purposes only. Clinical practice guidelines and drug information can change; always verify current prescribing information, institutional protocols, and patient-specific factors with a qualified healthcare professional before administering or prescribing medication.